Published Online: Tuesday, May 1, 2007

A new class of drugs—sandwiched between prescription and OTC medications and available only from pharmacists—is under active consideration by top FDA regulators. Word of the FDA's interest in the proposed new "behind-the-counter"(BTC) class of drugs surfaced during an address by FDA Pharmacy Affairs Director Ilisa B.G. Bernstein, PharmD, JD, at the American Pharmacists Association's (APhA) Annual Meeting in Atlanta, Ga.

Although critics of a new third class of drugs contend that limiting these medicines to sale in pharmacies would restrict consumer access to medication, FDA officials insist that their BTC plan would have just the opposite effect. According to Dr. Bernstein, the goal of the plan is to increase patient access to certain medicines that would otherwise require a prescription.

APhA—a longtime advocate of a pharmacist-only third class of drugs—welcomed the FDA's interest in the plan and predicted that patients would benefit from the change.

A number of other countries already have a pharmacist-only third class of drugs, but creating such a system in the United States would require action by Congress as well as the FDA.

For a related article, visit ePharmacy Times at Newsletter.cfm?ID=4511.

Latest Articles
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Latest Issues